Hormone Replacement Therapy May Increase Risk for Vulvovaginal Candidiasis

Vulvovaginal candidasis is a common condition involving infection of the vulva and vagina with Candida fungi. About 5% of all women will experience chronic or repeated episodes of vulvovaginal candidasis.     

Gayle Fischer et al.  Vulvovaginal candidiasis in posthormonal women: The role of hormone replacement therapy.  Journal of Lower Genital Tract Disease 2011;15:263-7. 

Symptoms of vulvovaginal candidiasis include itching, soreness, irritation, vaginal discharge, and pain and discomfort during urinatation and/or sexual intercourse.

Use of estrogen replacement therapy in postmenopausal and perimenopausal women may increase risk of vulvovaginal candidiasis. A study of 149 Australian postmenopausal women with vulvar conditions reported that 34 of 70 (48.5%) women on hormone replacement therapy had positive vaginal swabs for Candida as compared to only 2 of 79 women (2.5%) not on hormone replacement therapy (p<0.001).



Related Articles and videos
{module Related Articles}

Share on facebook
Share on Facebook
Share on reddit
Share on Reddit
Share on email
Share via Email
Share on twitter
Share on Twitter

Leave a Reply